The stock of GlaxoSmithKline Pharmaceuticals (GSK Pharma) is down 14 per cent since February, underperforming the BSE Healthcare index, which is up about 5.7 per cent during this period. From its highs in early February, the Indian unit of the pharma multinational has lost a fifth of its market capitalisation (mcap). While a weak December quarter performance and downgrades have led to muted returns, most brokerages have a neutral stance, given the valuation concerns.
Even as top pharmaceutical peers delivered double-digit growth in the December quarter, sales of GSK Pharma, at 805 crore, were flat over the year-ago quarter. They were also less than the ₹860 crore estimated by brokerages.
The flattish revenue was on account of price cuts in key brands and a slowdown in the acute segment. Prices of antibiotic Ceftum and ointment T-Bact were cut by 57 per cent and 30 per cent, respectively, though some of this was offset by volume growth on a sequential basis.
This story is from the April 12, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the April 12, 2024 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Kansai Nerolac needs fresh coat to improve margins
Kansai Nerolac Paints has seen its market capitalisation (mcap) erode by over 5 per cent since May 3 after posting a subpar performance in the fourth quarter of 2023-24.
Cipla Promoters Offload 2.53% Stake For 2,637 Cr
Proceeds to be used for creating liquidity’ for philanthropy
US Protests: Why Are Faculty Voices Muted?
The silence of faculty underscores a shift where the pursuit of academic values takes a back seat to preserving financial interests
India's weight in MSCI equity index hits another high
India's weight in MSCI's Global Standard index, which tracks emerging market stocks, has risen to another record high, boosting prospects of more inflows into its equity markets.
Foreign investors most short on India stocks since 2012
Foreign investors are the most pessimistic in over a decade on Indian stocks amid speculation over Prime Minister Narendra Modi's party winning fewer seats in the ongoing national elections than previously estimated.
Raft of exemptions for government companies covers Sebi, MCA, CCI
Regulatory exemptions for government companies have been granted by multiple authorities. The Securities and Exchange Board of India (Sebi) has provided a raft of exemptions to listed public sector entities.
LIC gets until 2027 for 10% public shareholding
L ife Insurance Corporation (LIC) of India has been granted a three-year extension by the Securities and Exchange Board of India (Sebi) to achieve a 10 per cent public shareholding, the state-owned firm announced to the exchanges on Wednesday.
Leaning in: Isha Ambani beyond Reliance Retail
Ambani means business. Not only when she is doing business she .leads Reliance Retail-but also when she is not. The latter was unmistakable on Wednesday, during her eight-minute 49second video address on the occasion of Information and Communications Technology (ICT) Day India 2024\".
A MATTER OF ACCESS
What is on the cards for the India-Asean FTA review
Diplomacy from the outside in
This is a compelling and lucidly written memoir of a distinguished academic who established himself as a diplomat and special envoy, turfusually reserved for career diplomats. SD Muni was appointed by Prime Minister Inder Kumar Gujral as India's ambassador to Laos in 1997.
